Akeso, Inc. (HKG: 9926)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 63.14B |
| Revenue (ttm) | 2.01B |
| Net Income (ttm) | -790.12M |
| Shares Out | 897.56M |
| EPS (ttm) | -0.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,832,629 |
| Open | 64.15 |
| Previous Close | 63.90 |
| Day's Range | 63.50 - 64.65 |
| 52-Week Range | 26.45 - 77.65 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 28, 2024 |
About Akeso
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovari... [Read more]
News
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ: SMMT), noting the company’s initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed...